|
Novartis Jumps on Hep C Bandwagon With Enanta Collaboration
Novartis is staking a claim in an increasingly competitive and crowded hepatitis C field, acquiring Enanta’s HCV drug EDP-239 for $34 million.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives